JP2013508405A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013508405A5 JP2013508405A5 JP2012535386A JP2012535386A JP2013508405A5 JP 2013508405 A5 JP2013508405 A5 JP 2013508405A5 JP 2012535386 A JP2012535386 A JP 2012535386A JP 2012535386 A JP2012535386 A JP 2012535386A JP 2013508405 A5 JP2013508405 A5 JP 2013508405A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- diazabicyclo
- triazol
- fluoro
- octane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 1H-pyrazol-1-yl Chemical group 0.000 claims 118
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 21
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 20
- 239000000126 substance Substances 0.000 claims 18
- 125000001475 halogen functional group Chemical group 0.000 claims 12
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 10
- 125000001607 1,2,3-triazol-1-yl group Chemical group [*]N1N=NC([H])=C1[H] 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 6
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 6
- SSJXIUAHEKJCMH-WDSKDSINSA-N (1s,2s)-cyclohexane-1,2-diamine Chemical compound N[C@H]1CCCC[C@@H]1N SSJXIUAHEKJCMH-WDSKDSINSA-N 0.000 claims 5
- 125000004262 quinoxalin-2-yl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N=C1* 0.000 claims 5
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims 4
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 4
- HBAPRWLCCBZDNA-UHFFFAOYSA-N 4-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidine Chemical compound CC1=NC=NC2=C1CCC2 HBAPRWLCCBZDNA-UHFFFAOYSA-N 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- SMUQFGGVLNAIOZ-UHFFFAOYSA-N quinaldine Chemical compound C1=CC=CC2=NC(C)=CC=C21 SMUQFGGVLNAIOZ-UHFFFAOYSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 3
- VZWOXDYRBDIHMA-UHFFFAOYSA-N 2-methyl-1,3-thiazole Chemical group CC1=NC=CS1 VZWOXDYRBDIHMA-UHFFFAOYSA-N 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- GKVDLTTVBNOGNJ-UHFFFAOYSA-N 2-methylpyrimidin-4-amine Chemical compound CC1=NC=CC(N)=N1 GKVDLTTVBNOGNJ-UHFFFAOYSA-N 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- JJOOKXUUVWIARB-UHFFFAOYSA-N 6-chloro-1,3-benzoxazole Chemical compound ClC1=CC=C2N=COC2=C1 JJOOKXUUVWIARB-UHFFFAOYSA-N 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- RZWKLEHRXNOKGT-UHFFFAOYSA-N CC=1C(=C(C=CC1)C=O)C1=CC=NN1 Chemical compound CC=1C(=C(C=CC1)C=O)C1=CC=NN1 RZWKLEHRXNOKGT-UHFFFAOYSA-N 0.000 claims 2
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010033307 Overweight Diseases 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 2
- 208000001871 Tachycardia Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 206010022437 insomnia Diseases 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- KDUWWQCGLSYDIY-UHFFFAOYSA-N n,n,2-trimethylpyrimidin-4-amine Chemical compound CN(C)C1=CC=NC(C)=N1 KDUWWQCGLSYDIY-UHFFFAOYSA-N 0.000 claims 2
- LAURYIYOSYVBIZ-UHFFFAOYSA-N n,n,4-trimethylpyrimidin-2-amine Chemical compound CN(C)C1=NC=CC(C)=N1 LAURYIYOSYVBIZ-UHFFFAOYSA-N 0.000 claims 2
- MSXIOWULDXZJLX-UHFFFAOYSA-N n,n-dimethylpyrimidin-4-amine Chemical compound CN(C)C1=CC=NC=N1 MSXIOWULDXZJLX-UHFFFAOYSA-N 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 235000020825 overweight Nutrition 0.000 claims 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000020685 sleep-wake disease Diseases 0.000 claims 2
- 230000006794 tachycardia Effects 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- ZERSCKSOBJMLBC-UHFFFAOYSA-N (2,6-dimethoxyphenyl)-(4-quinoxalin-6-yl-4,7-diazabicyclo[4.2.0]octan-7-yl)methanone Chemical compound COC1=CC=CC(OC)=C1C(=O)N1C2CN(C=3C=C4N=CC=NC4=CC=3)CCC2C1 ZERSCKSOBJMLBC-UHFFFAOYSA-N 0.000 claims 1
- MERAYSGZQADQGE-UHFFFAOYSA-N (2,6-dimethoxyphenyl)-[4-(4-phenylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]methanone Chemical compound COC1=CC=CC(OC)=C1C(=O)N1C2CN(C=3N=C(C=CN=3)C=3C=CC=CC=3)CCC2C1 MERAYSGZQADQGE-UHFFFAOYSA-N 0.000 claims 1
- USOABOIEIQKGGQ-UHFFFAOYSA-N (2-bromophenyl)-[3-(4,6-dimethylpyrimidin-2-yl)-3,6-diazabicyclo[3.2.0]heptan-6-yl]methanone Chemical compound CC1=CC(C)=NC(N2CC3N(CC3C2)C(=O)C=2C(=CC=CC=2)Br)=N1 USOABOIEIQKGGQ-UHFFFAOYSA-N 0.000 claims 1
- GXDONUFNDCCJQI-UHFFFAOYSA-N (2-bromophenyl)-[3-(4-methylpyrimidin-2-yl)-3,6-diazabicyclo[3.2.0]heptan-6-yl]methanone Chemical compound CC1=CC=NC(N2CC3N(CC3C2)C(=O)C=2C(=CC=CC=2)Br)=N1 GXDONUFNDCCJQI-UHFFFAOYSA-N 0.000 claims 1
- JXXXJWSNTPQUSL-UHFFFAOYSA-N (2-phenylphenyl)-(3-quinoxalin-2-yl-3,6-diazabicyclo[3.2.0]heptan-6-yl)methanone Chemical compound C1C2CN(C=3N=C4C=CC=CC4=NC=3)CC2N1C(=O)C1=CC=CC=C1C1=CC=CC=C1 JXXXJWSNTPQUSL-UHFFFAOYSA-N 0.000 claims 1
- NCRSYKPNXDTNQA-UHFFFAOYSA-N (2-phenylphenyl)-(4-quinoxalin-2-yl-4,7-diazabicyclo[4.2.0]octan-7-yl)methanone Chemical compound C1C2CCN(C=3N=C4C=CC=CC4=NC=3)CC2N1C(=O)C1=CC=CC=C1C1=CC=CC=C1 NCRSYKPNXDTNQA-UHFFFAOYSA-N 0.000 claims 1
- WWHREMBTHQBQAA-UHFFFAOYSA-N (2-phenylphenyl)-[3-(4-phenylpyrimidin-2-yl)-3,6-diazabicyclo[3.2.0]heptan-6-yl]methanone Chemical compound C=1C=CC=C(C=2C=CC=CC=2)C=1C(=O)N(C1C2)CC1CN2C(N=1)=NC=CC=1C1=CC=CC=C1 WWHREMBTHQBQAA-UHFFFAOYSA-N 0.000 claims 1
- FCAOJQYTXNQTOI-UHFFFAOYSA-N (2-phenylphenyl)-[4-(4-phenylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]methanone Chemical compound C=1C=CC=C(C=2C=CC=CC=2)C=1C(=O)N(C1C2)CC1CCN2C(N=1)=NC=CC=1C1=CC=CC=C1 FCAOJQYTXNQTOI-UHFFFAOYSA-N 0.000 claims 1
- KLIDCXVFHGNTTM-UHFFFAOYSA-N 2,6-dimethoxyphenol Chemical group COC1=CC=CC(OC)=C1O KLIDCXVFHGNTTM-UHFFFAOYSA-N 0.000 claims 1
- YHUWINJRLYIHCD-UHFFFAOYSA-N 2-[7-(2,5-dimethylphenyl)sulfonyl-4,7-diazabicyclo[4.2.0]octan-4-yl]quinoxaline Chemical compound CC1=CC=C(C)C(S(=O)(=O)N2C3CN(CCC3C2)C=2N=C3C=CC=CC3=NC=2)=C1 YHUWINJRLYIHCD-UHFFFAOYSA-N 0.000 claims 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims 1
- YESCPKTWTUCNTK-UHFFFAOYSA-N 2-fluoro-6-(triazol-2-yl)benzaldehyde Chemical compound FC1=C(C(=CC=C1)N1N=CC=N1)C=O YESCPKTWTUCNTK-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- AGFPGULYIMKQGT-UHFFFAOYSA-N 3-fluoro-2-(1H-pyrazol-5-yl)benzaldehyde Chemical compound FC=1C(=C(C=CC=1)C=O)C=1NN=CC=1 AGFPGULYIMKQGT-UHFFFAOYSA-N 0.000 claims 1
- QSYWKQLZNHTFCV-UHFFFAOYSA-N 3-fluoro-2-(triazol-2-yl)benzaldehyde Chemical compound FC1=CC=CC(C=O)=C1N1N=CC=N1 QSYWKQLZNHTFCV-UHFFFAOYSA-N 0.000 claims 1
- OBFNEMXIPDVHRI-UHFFFAOYSA-N 4-fluoro-2-pyrimidin-2-ylbenzaldehyde Chemical compound FC1=CC(=C(C=C1)C=O)C1=NC=CC=N1 OBFNEMXIPDVHRI-UHFFFAOYSA-N 0.000 claims 1
- ZJTUYXLOPPDBGH-UHFFFAOYSA-N 4-methoxy-2-(triazol-2-yl)benzaldehyde Chemical compound COC1=CC=C(C=O)C(N2N=CC=N2)=C1 ZJTUYXLOPPDBGH-UHFFFAOYSA-N 0.000 claims 1
- NUZBBIHTIXZDDY-UHFFFAOYSA-N 7-(2,5-dimethylphenyl)sulfonyl-4-(4-phenylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octane Chemical compound CC1=CC=C(C)C(S(=O)(=O)N2C3CN(CCC3C2)C=2N=C(C=CN=2)C=2C=CC=CC=2)=C1 NUZBBIHTIXZDDY-UHFFFAOYSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 208000008035 Back Pain Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010007556 Cardiac failure acute Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- PGEXEBHDXNLTIE-UHFFFAOYSA-N FC=1C(=C(C=CC1)C=O)C1=CC(=NO1)C Chemical compound FC=1C(=C(C=CC1)C=O)C1=CC(=NO1)C PGEXEBHDXNLTIE-UHFFFAOYSA-N 0.000 claims 1
- STLYQTNIULBKGY-UHFFFAOYSA-N FC=1C(=C(C=CC1)C=O)C1=CC=NO1 Chemical compound FC=1C(=C(C=CC1)C=O)C1=CC=NO1 STLYQTNIULBKGY-UHFFFAOYSA-N 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 102000002512 Orexin Human genes 0.000 claims 1
- 108050000742 Orexin Receptor Proteins 0.000 claims 1
- 102000008834 Orexin receptor Human genes 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- ZFZULBCQSGGOHR-DNVCBOLYSA-N [(1r,6s)-4-(4,5-dimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[5-fluoro-2-(triazol-2-yl)phenyl]methanone Chemical compound N1=C(C)C(C)=CN=C1N1C[C@H]2N(C(=O)C=3C(=CC=C(F)C=3)N3N=CC=N3)C[C@H]2CC1 ZFZULBCQSGGOHR-DNVCBOLYSA-N 0.000 claims 1
- DBODIMKUPBUYBB-SJLPKXTDSA-N [(1r,6s)-4-(4,5-dimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[6-methyl-2-(triazol-1-yl)pyridin-3-yl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C2=CC=C(N=C2N2N=NC=C2)C)CN1C1=NC=C(C)C(C)=N1 DBODIMKUPBUYBB-SJLPKXTDSA-N 0.000 claims 1
- VNNKBQGOFHYHOZ-VQIMIIECSA-N [(1r,6s)-4-(4,6-dimethylpyridin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[2-fluoro-6-(triazol-2-yl)phenyl]methanone Chemical compound CC1=CC(C)=NC(N2C[C@H]3N(C[C@H]3CC2)C(=O)C=2C(=CC=CC=2F)N2N=CC=N2)=C1 VNNKBQGOFHYHOZ-VQIMIIECSA-N 0.000 claims 1
- ARCNMXAESGIZJJ-VQIMIIECSA-N [(1r,6s)-4-(4,6-dimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-(3-fluoro-2-pyrazol-1-ylphenyl)methanone Chemical compound CC1=CC(C)=NC(N2C[C@H]3N(C[C@H]3CC2)C(=O)C=2C(=C(F)C=CC=2)N2N=CC=C2)=N1 ARCNMXAESGIZJJ-VQIMIIECSA-N 0.000 claims 1
- RAWRQCGINRXFGJ-VQIMIIECSA-N [(1r,6s)-4-(4,6-dimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-(3-fluoro-2-pyrimidin-2-ylphenyl)methanone Chemical compound CC1=CC(C)=NC(N2C[C@H]3N(C[C@H]3CC2)C(=O)C=2C(=C(F)C=CC=2)C=2N=CC=CN=2)=N1 RAWRQCGINRXFGJ-VQIMIIECSA-N 0.000 claims 1
- RNPBAIRMGAFCTD-UYAOXDASSA-N [(1r,6s)-4-(4,6-dimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-(3-methyl-2-pyrazol-1-ylphenyl)methanone Chemical compound CC1=CC(C)=NC(N2C[C@H]3N(C[C@H]3CC2)C(=O)C=2C(=C(C)C=CC=2)N2N=CC=C2)=N1 RNPBAIRMGAFCTD-UYAOXDASSA-N 0.000 claims 1
- NFHNWNGGAXTAHB-VQIMIIECSA-N [(1r,6s)-4-(4,6-dimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]methanone Chemical compound CC1=NOC(C=2C(=CC=CC=2)C(=O)N2[C@@H]3CN(CC[C@@H]3C2)C=2N=C(C)C=C(C)N=2)=N1 NFHNWNGGAXTAHB-VQIMIIECSA-N 0.000 claims 1
- QMUHLWWRQXORGR-CRAIPNDOSA-N [(1r,6s)-4-(4,6-dimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[2-fluoro-6-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]methanone Chemical compound CC1=NOC(C=2C(=C(F)C=CC=2)C(=O)N2[C@@H]3CN(CC[C@@H]3C2)C=2N=C(C)C=C(C)N=2)=N1 QMUHLWWRQXORGR-CRAIPNDOSA-N 0.000 claims 1
- GDIQDZVRMKTDML-CRAIPNDOSA-N [(1r,6s)-4-(4,6-dimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[2-fluoro-6-(triazol-2-yl)phenyl]methanone Chemical compound CC1=CC(C)=NC(N2C[C@H]3N(C[C@H]3CC2)C(=O)C=2C(=CC=CC=2F)N2N=CC=N2)=N1 GDIQDZVRMKTDML-CRAIPNDOSA-N 0.000 claims 1
- VQLZITAIIORYNU-DNVCBOLYSA-N [(1r,6s)-4-(4,6-dimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[3-fluoro-2-(1h-pyrazol-5-yl)phenyl]methanone Chemical compound CC1=CC(C)=NC(N2C[C@H]3N(C[C@H]3CC2)C(=O)C=2C(=C(F)C=CC=2)C=2NN=CC=2)=N1 VQLZITAIIORYNU-DNVCBOLYSA-N 0.000 claims 1
- CNVDHNKVDSWDHK-CRAIPNDOSA-N [(1r,6s)-4-(4,6-dimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[3-fluoro-2-(triazol-1-yl)phenyl]methanone Chemical compound CC1=CC(C)=NC(N2C[C@H]3N(C[C@H]3CC2)C(=O)C=2C(=C(F)C=CC=2)N2N=NC=C2)=N1 CNVDHNKVDSWDHK-CRAIPNDOSA-N 0.000 claims 1
- KPLJXBDVXNWNGI-CRAIPNDOSA-N [(1r,6s)-4-(4,6-dimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[3-fluoro-2-(triazol-2-yl)phenyl]methanone Chemical compound CC1=CC(C)=NC(N2C[C@H]3N(C[C@H]3CC2)C(=O)C=2C(=C(F)C=CC=2)N2N=CC=N2)=N1 KPLJXBDVXNWNGI-CRAIPNDOSA-N 0.000 claims 1
- MUKSCISAZPPELV-SJLPKXTDSA-N [(1r,6s)-4-(4,6-dimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[3-methoxy-2-(triazol-1-yl)phenyl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C=2C=CC=C(C=2N2N=NC=C2)OC)CN1C1=NC(C)=CC(C)=N1 MUKSCISAZPPELV-SJLPKXTDSA-N 0.000 claims 1
- RHJBVNFMVXMMQA-SJLPKXTDSA-N [(1r,6s)-4-(4,6-dimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[3-methoxy-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C=2C=CC=C(C=2N2N=CC=N2)OC)CN1C1=NC(C)=CC(C)=N1 RHJBVNFMVXMMQA-SJLPKXTDSA-N 0.000 claims 1
- KALRYPOHHCRTNN-IEBWSBKVSA-N [(1r,6s)-4-(4,6-dimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[3-methyl-2-(triazol-1-yl)phenyl]methanone Chemical compound CC1=CC(C)=NC(N2C[C@H]3N(C[C@H]3CC2)C(=O)C=2C(=C(C)C=CC=2)N2N=NC=C2)=N1 KALRYPOHHCRTNN-IEBWSBKVSA-N 0.000 claims 1
- IPKRWZKTQZLMOQ-OXQOHEQNSA-N [(1r,6s)-4-(4,6-dimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[4-methoxy-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C2=CC=C(C=C2N2N=CC=N2)OC)CN1C1=NC(C)=CC(C)=N1 IPKRWZKTQZLMOQ-OXQOHEQNSA-N 0.000 claims 1
- FLWWBLDVCVQTRI-DNVCBOLYSA-N [(1r,6s)-4-(4,6-dimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[5-fluoro-2-(triazol-2-yl)phenyl]methanone Chemical compound CC1=CC(C)=NC(N2C[C@H]3N(C[C@H]3CC2)C(=O)C=2C(=CC=C(F)C=2)N2N=CC=N2)=N1 FLWWBLDVCVQTRI-DNVCBOLYSA-N 0.000 claims 1
- XTBUKDIQTIIDEW-OXQOHEQNSA-N [(1r,6s)-4-(4,6-dimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C=2C(=CC=C(C=2)OC)N2N=CC=N2)CN1C1=NC(C)=CC(C)=N1 XTBUKDIQTIIDEW-OXQOHEQNSA-N 0.000 claims 1
- MTLHNBTZPPYZMD-SJLPKXTDSA-N [(1r,6s)-4-(4,6-dimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[6-methyl-2-(triazol-1-yl)pyridin-3-yl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C2=CC=C(N=C2N2N=NC=C2)C)CN1C1=NC(C)=CC(C)=N1 MTLHNBTZPPYZMD-SJLPKXTDSA-N 0.000 claims 1
- DHGNKEKRMDXCQR-CXAGYDPISA-N [(1r,6s)-4-(4-aminopyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C=2C(=CC=C(C=2)OC)N2N=CC=N2)CN1C1=NC=CC(N)=N1 DHGNKEKRMDXCQR-CXAGYDPISA-N 0.000 claims 1
- MBJQSBKKTPPLFW-SJLPKXTDSA-N [(1r,6s)-4-(4-methylpyridin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[6-methyl-2-(triazol-1-yl)pyridin-3-yl]methanone Chemical compound CC1=CC=NC(N2C[C@H]3N(C[C@H]3CC2)C(=O)C=2C(=NC(C)=CC=2)N2N=NC=C2)=C1 MBJQSBKKTPPLFW-SJLPKXTDSA-N 0.000 claims 1
- SCAZJSXMMAEAFL-CRAIPNDOSA-N [(1r,6s)-4-(5-chloro-4,6-dimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]methanone Chemical compound CC1=NOC(C=2C(=CC=CC=2)C(=O)N2[C@@H]3CN(CC[C@@H]3C2)C=2N=C(C)C(Cl)=C(C)N=2)=N1 SCAZJSXMMAEAFL-CRAIPNDOSA-N 0.000 claims 1
- ZNRGINVDUKPUGG-RDTXWAMCSA-N [(1r,6s)-4-(5-chloro-4-methylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]methanone Chemical compound CC1=NOC(C=2C(=CC=CC=2)C(=O)N2[C@@H]3CN(CC[C@@H]3C2)C=2N=C(C)C(Cl)=CN=2)=N1 ZNRGINVDUKPUGG-RDTXWAMCSA-N 0.000 claims 1
- FTJRZQDAPUBTRL-CRAIPNDOSA-N [(1r,6s)-4-(5-fluoro-4,6-dimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]methanone Chemical compound CC1=NOC(C=2C(=CC=CC=2)C(=O)N2[C@@H]3CN(CC[C@@H]3C2)C=2N=C(C)C(F)=C(C)N=2)=N1 FTJRZQDAPUBTRL-CRAIPNDOSA-N 0.000 claims 1
- QAWGVYWAZNEIQG-RHSMWYFYSA-N [(1r,6s)-4-(5-fluoro-4,6-dimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[3-fluoro-2-(1,2-oxazol-5-yl)phenyl]methanone Chemical compound CC1=C(F)C(C)=NC(N2C[C@H]3N(C[C@H]3CC2)C(=O)C=2C(=C(F)C=CC=2)C=2ON=CC=2)=N1 QAWGVYWAZNEIQG-RHSMWYFYSA-N 0.000 claims 1
- GZVFQNVGXNUCDW-RDTXWAMCSA-N [(1r,6s)-4-(5-fluoro-4,6-dimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[3-fluoro-2-(1h-pyrazol-5-yl)phenyl]methanone Chemical compound CC1=C(F)C(C)=NC(N2C[C@H]3N(C[C@H]3CC2)C(=O)C=2C(=C(F)C=CC=2)C=2NN=CC=2)=N1 GZVFQNVGXNUCDW-RDTXWAMCSA-N 0.000 claims 1
- GJJBYNIKRYEDKK-CRAIPNDOSA-N [(1r,6s)-4-(5-fluoro-4,6-dimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[3-fluoro-2-(3-methyl-1,2-oxazol-5-yl)phenyl]methanone Chemical compound O1N=C(C)C=C1C1=C(F)C=CC=C1C(=O)N1[C@@H]2CN(C=3N=C(C)C(F)=C(C)N=3)CC[C@@H]2C1 GJJBYNIKRYEDKK-CRAIPNDOSA-N 0.000 claims 1
- MTPLZRJKIYAGIP-CXAGYDPISA-N [(1r,6s)-4-(5-fluoro-4-methylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[3-fluoro-2-(triazol-2-yl)phenyl]methanone Chemical compound C1=C(F)C(C)=NC(N2C[C@H]3N(C[C@H]3CC2)C(=O)C=2C(=C(F)C=CC=2)N2N=CC=N2)=N1 MTPLZRJKIYAGIP-CXAGYDPISA-N 0.000 claims 1
- MGMPEAOCKQATPX-AUUYWEPGSA-N [(1r,6s)-4-(5-fluoro-4-methylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C=2C(=CC=C(C=2)OC)N2N=CC=N2)CN1C1=NC=C(F)C(C)=N1 MGMPEAOCKQATPX-AUUYWEPGSA-N 0.000 claims 1
- PXPUTKAXBSAKFK-RHSMWYFYSA-N [(1r,6s)-4-(5-fluoro-4-methylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[6-methyl-2-(triazol-1-yl)pyridin-3-yl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C2=CC=C(N=C2N2N=NC=C2)C)CN1C1=NC=C(F)C(C)=N1 PXPUTKAXBSAKFK-RHSMWYFYSA-N 0.000 claims 1
- YQBCCVKQJDKKLH-RDTXWAMCSA-N [(1r,6s)-4-(6-chloro-1,3-benzoxazol-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[6-methyl-2-(triazol-1-yl)pyridin-3-yl]methanone Chemical compound N=1C(C)=CC=C(C(=O)N2[C@@H]3CN(CC[C@@H]3C2)C=2OC3=CC(Cl)=CC=C3N=2)C=1N1C=CN=N1 YQBCCVKQJDKKLH-RDTXWAMCSA-N 0.000 claims 1
- BWZPGVXWIPAXHT-OXQOHEQNSA-N [(1r,6s)-4-[2-(dimethylamino)-6-methylpyrimidin-4-yl]-4,7-diazabicyclo[4.2.0]octan-7-yl]-[4-methoxy-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C2=CC=C(C=C2N2N=CC=N2)OC)CN1C1=CC(C)=NC(N(C)C)=N1 BWZPGVXWIPAXHT-OXQOHEQNSA-N 0.000 claims 1
- XYDFOQGVMNVZED-OXQOHEQNSA-N [(1r,6s)-4-[2-(dimethylamino)-6-methylpyrimidin-4-yl]-4,7-diazabicyclo[4.2.0]octan-7-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C=2C(=CC=C(C=2)OC)N2N=CC=N2)CN1C1=CC(C)=NC(N(C)C)=N1 XYDFOQGVMNVZED-OXQOHEQNSA-N 0.000 claims 1
- JZNNDXCXDLORRN-OXQOHEQNSA-N [(1r,6s)-4-[6-(dimethylamino)-2-methylpyrimidin-4-yl]-4,7-diazabicyclo[4.2.0]octan-7-yl]-[4-methoxy-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C2=CC=C(C=C2N2N=CC=N2)OC)CN1C1=CC(N(C)C)=NC(C)=N1 JZNNDXCXDLORRN-OXQOHEQNSA-N 0.000 claims 1
- WZEYQMOJZMWFRR-OXQOHEQNSA-N [(1r,6s)-4-[6-(dimethylamino)-2-methylpyrimidin-4-yl]-4,7-diazabicyclo[4.2.0]octan-7-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C=2C(=CC=C(C=2)OC)N2N=CC=N2)CN1C1=CC(N(C)C)=NC(C)=N1 WZEYQMOJZMWFRR-OXQOHEQNSA-N 0.000 claims 1
- MQKFUBZBDXWABR-CRAIPNDOSA-N [(1r,6s)-4-[6-(dimethylamino)pyrimidin-4-yl]-4,7-diazabicyclo[4.2.0]octan-7-yl]-[2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]methanone Chemical compound C1=NC(N(C)C)=CC(N2C[C@H]3N(C[C@H]3CC2)C(=O)C=2C(=CC=CC=2)C=2ON=C(C)N=2)=N1 MQKFUBZBDXWABR-CRAIPNDOSA-N 0.000 claims 1
- MXTVTJUCDQIPFH-CRAIPNDOSA-N [(1r,6s)-4-[6-(dimethylamino)pyrimidin-4-yl]-4,7-diazabicyclo[4.2.0]octan-7-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C1=NC(N(C)C)=CC(N2C[C@H]3N(C[C@H]3CC2)C(=O)C=2C(=CC=CC=2)N2N=CC=N2)=N1 MXTVTJUCDQIPFH-CRAIPNDOSA-N 0.000 claims 1
- WPXGIWSOQDTKFO-DNVCBOLYSA-N [(1r,6s)-4-[6-(dimethylamino)pyrimidin-4-yl]-4,7-diazabicyclo[4.2.0]octan-7-yl]-[4-methoxy-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C2=CC=C(C=C2N2N=CC=N2)OC)CN1C1=CC(N(C)C)=NC=N1 WPXGIWSOQDTKFO-DNVCBOLYSA-N 0.000 claims 1
- FSRQWMZGEOOPHT-DNVCBOLYSA-N [(1r,6s)-4-[6-(dimethylamino)pyrimidin-4-yl]-4,7-diazabicyclo[4.2.0]octan-7-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C=2C(=CC=C(C=2)OC)N2N=CC=N2)CN1C1=CC(N(C)C)=NC=N1 FSRQWMZGEOOPHT-DNVCBOLYSA-N 0.000 claims 1
- YJDODUFNQDTQKZ-REWPJTCUSA-N [(1s,6r)-4-(4,6-dimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-(2-phenylphenyl)methanone Chemical compound CC1=CC(C)=NC(N2C[C@@H]3N(C[C@@H]3CC2)C(=O)C=2C(=CC=CC=2)C=2C=CC=CC=2)=N1 YJDODUFNQDTQKZ-REWPJTCUSA-N 0.000 claims 1
- UJSDQRUUAHJSND-PXNSSMCTSA-N [(1s,6r)-4-(4,6-dimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-(2-thiophen-2-ylphenyl)methanone Chemical compound CC1=CC(C)=NC(N2C[C@@H]3N(C[C@@H]3CC2)C(=O)C=2C(=CC=CC=2)C=2SC=CC=2)=N1 UJSDQRUUAHJSND-PXNSSMCTSA-N 0.000 claims 1
- GDIQDZVRMKTDML-YJBOKZPZSA-N [(1s,6r)-4-(4,6-dimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-[2-fluoro-6-(triazol-2-yl)phenyl]methanone Chemical compound CC1=CC(C)=NC(N2C[C@@H]3N(C[C@@H]3CC2)C(=O)C=2C(=CC=CC=2F)N2N=CC=N2)=N1 GDIQDZVRMKTDML-YJBOKZPZSA-N 0.000 claims 1
- KNERPANAKIIIDU-YLJYHZDGSA-N [2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-[(1r,6s)-4-(4,5,6-trimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]methanone Chemical compound CC1=NOC(C=2C(=CC=CC=2)C(=O)N2[C@@H]3CN(CC[C@@H]3C2)C=2N=C(C)C(C)=C(C)N=2)=N1 KNERPANAKIIIDU-YLJYHZDGSA-N 0.000 claims 1
- SZKASESVFVXQAK-UZUQRXQVSA-N [2-fluoro-6-(triazol-2-yl)phenyl]-[(1r,6s)-4-(2-methylquinolin-4-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]methanone Chemical compound C([C@H]1CCN(C[C@H]11)C=2C=C(N=C3C=CC=CC3=2)C)N1C(=O)C1=C(F)C=CC=C1N1N=CC=N1 SZKASESVFVXQAK-UZUQRXQVSA-N 0.000 claims 1
- ZDIDFEWWLZIXGF-VQIMIIECSA-N [2-fluoro-6-(triazol-2-yl)phenyl]-[(1r,6s)-4-(4,5,6-trimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]methanone Chemical compound CC1=C(C)C(C)=NC(N2C[C@H]3N(C[C@H]3CC2)C(=O)C=2C(=CC=CC=2F)N2N=CC=N2)=N1 ZDIDFEWWLZIXGF-VQIMIIECSA-N 0.000 claims 1
- NPXVZFRHSSBVEF-IUODEOHRSA-N [2-fluoro-6-(triazol-2-yl)phenyl]-[(1r,6s)-4-[4-(trifluoromethyl)pyrimidin-2-yl]-4,7-diazabicyclo[4.2.0]octan-7-yl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C2=C(C=CC=C2F)N2N=CC=N2)CN1C1=NC=CC(C(F)(F)F)=N1 NPXVZFRHSSBVEF-IUODEOHRSA-N 0.000 claims 1
- VPFCLKHXIUNDJX-OPAMFIHVSA-N [2-fluoro-6-(triazol-2-yl)phenyl]-[(1r,6s)-4-quinolin-4-yl-4,7-diazabicyclo[4.2.0]octan-7-yl]methanone Chemical compound N1([C@@H]2CN(CC[C@@H]2C1)C=1C2=CC=CC=C2N=CC=1)C(=O)C=1C(F)=CC=CC=1N1N=CC=N1 VPFCLKHXIUNDJX-OPAMFIHVSA-N 0.000 claims 1
- NPXVZFRHSSBVEF-WFASDCNBSA-N [2-fluoro-6-(triazol-2-yl)phenyl]-[(1s,6r)-4-[4-(trifluoromethyl)pyrimidin-2-yl]-4,7-diazabicyclo[4.2.0]octan-7-yl]methanone Chemical compound C([C@H]1CN([C@H]1C1)C(=O)C2=C(C=CC=C2F)N2N=CC=N2)CN1C1=NC=CC(C(F)(F)F)=N1 NPXVZFRHSSBVEF-WFASDCNBSA-N 0.000 claims 1
- DUZGNMGVQFOPMO-UHFFFAOYSA-N [2-fluoro-6-(triazol-2-yl)phenyl]-[3-[4-methyl-6-(trifluoromethyl)pyrimidin-2-yl]-3,6-diazabicyclo[3.2.0]heptan-6-yl]methanone Chemical compound CC1=CC(C(F)(F)F)=NC(N2CC3N(CC3C2)C(=O)C=2C(=CC=CC=2F)N2N=CC=N2)=N1 DUZGNMGVQFOPMO-UHFFFAOYSA-N 0.000 claims 1
- NAQKCUDYBFCCNK-UHFFFAOYSA-N [3-(3,6-dimethylpyrazin-2-yl)-3,6-diazabicyclo[3.2.0]heptan-6-yl]-[2-fluoro-6-(triazol-2-yl)phenyl]methanone Chemical compound CC1=CN=C(C)C(N2CC3N(CC3C2)C(=O)C=2C(=CC=CC=2F)N2N=CC=N2)=N1 NAQKCUDYBFCCNK-UHFFFAOYSA-N 0.000 claims 1
- VFIAMRFRWFFWTA-UHFFFAOYSA-N [3-(4,6-dimethoxypyrimidin-2-yl)-3,6-diazabicyclo[3.2.0]heptan-6-yl]-[2-fluoro-6-(triazol-2-yl)phenyl]methanone Chemical compound COC1=CC(OC)=NC(N2CC3N(CC3C2)C(=O)C=2C(=CC=CC=2F)N2N=CC=N2)=N1 VFIAMRFRWFFWTA-UHFFFAOYSA-N 0.000 claims 1
- OFXUUYPFMNNTIU-UHFFFAOYSA-N [3-(4,6-dimethylpyrimidin-2-yl)-3,6-diazabicyclo[3.2.0]heptan-6-yl]-(2-phenylphenyl)methanone Chemical compound CC1=CC(C)=NC(N2CC3N(CC3C2)C(=O)C=2C(=CC=CC=2)C=2C=CC=CC=2)=N1 OFXUUYPFMNNTIU-UHFFFAOYSA-N 0.000 claims 1
- RUUBWSXPUVGENA-UHFFFAOYSA-N [3-(4,6-dimethylpyrimidin-2-yl)-3,6-diazabicyclo[3.2.0]heptan-6-yl]-(2-thiophen-2-ylphenyl)methanone Chemical compound CC1=CC(C)=NC(N2CC3N(CC3C2)C(=O)C=2C(=CC=CC=2)C=2SC=CC=2)=N1 RUUBWSXPUVGENA-UHFFFAOYSA-N 0.000 claims 1
- GWVNNSNIAOPTHK-UHFFFAOYSA-N [3-(4,6-dimethylpyrimidin-2-yl)-3,6-diazabicyclo[3.2.0]heptan-6-yl]-(5-fluoro-2-pyrimidin-2-ylphenyl)methanone Chemical compound CC1=CC(C)=NC(N2CC3N(CC3C2)C(=O)C=2C(=CC=C(F)C=2)C=2N=CC=CN=2)=N1 GWVNNSNIAOPTHK-UHFFFAOYSA-N 0.000 claims 1
- HXQRNACRFYBQKE-UHFFFAOYSA-N [3-(4,6-dimethylpyrimidin-2-yl)-3,6-diazabicyclo[3.2.0]heptan-6-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound CC1=CC(C)=NC(N2CC3N(CC3C2)C(=O)C=2C(=CC=CC=2)N2N=CC=N2)=N1 HXQRNACRFYBQKE-UHFFFAOYSA-N 0.000 claims 1
- XZELEIIAULBWNR-UHFFFAOYSA-N [3-(4,6-dimethylpyrimidin-2-yl)-3,6-diazabicyclo[3.2.0]heptan-6-yl]-[2-fluoro-6-(triazol-2-yl)phenyl]methanone Chemical compound CC1=CC(C)=NC(N2CC3N(CC3C2)C(=O)C=2C(=CC=CC=2F)N2N=CC=N2)=N1 XZELEIIAULBWNR-UHFFFAOYSA-N 0.000 claims 1
- UDXTYHKJPIAMNH-UHFFFAOYSA-N [3-(4,6-dimethylpyrimidin-2-yl)-3,6-diazabicyclo[3.2.0]heptan-6-yl]-[3-fluoro-2-(triazol-2-yl)phenyl]methanone Chemical compound CC1=CC(C)=NC(N2CC3N(CC3C2)C(=O)C=2C(=C(F)C=CC=2)N2N=CC=N2)=N1 UDXTYHKJPIAMNH-UHFFFAOYSA-N 0.000 claims 1
- VHRBCQYXYFTSKC-UHFFFAOYSA-N [3-(4-methylpyrimidin-2-yl)-3,6-diazabicyclo[3.2.0]heptan-6-yl]-(2-phenylphenyl)methanone Chemical compound CC1=CC=NC(N2CC3N(CC3C2)C(=O)C=2C(=CC=CC=2)C=2C=CC=CC=2)=N1 VHRBCQYXYFTSKC-UHFFFAOYSA-N 0.000 claims 1
- ULIIXYYYZPFWOG-UHFFFAOYSA-N [3-(4-methylpyrimidin-2-yl)-3,6-diazabicyclo[3.2.0]heptan-6-yl]-(2-thiophen-2-ylphenyl)methanone Chemical compound CC1=CC=NC(N2CC3N(CC3C2)C(=O)C=2C(=CC=CC=2)C=2SC=CC=2)=N1 ULIIXYYYZPFWOG-UHFFFAOYSA-N 0.000 claims 1
- KLPFRSAEGIGZFZ-VQIMIIECSA-N [3-fluoro-2-(1,2-oxazol-5-yl)phenyl]-[(1r,6s)-4-(4,5,6-trimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]methanone Chemical compound CC1=C(C)C(C)=NC(N2C[C@H]3N(C[C@H]3CC2)C(=O)C=2C(=C(F)C=CC=2)C=2ON=CC=2)=N1 KLPFRSAEGIGZFZ-VQIMIIECSA-N 0.000 claims 1
- LLRGSYGXXWURGI-CXAGYDPISA-N [3-fluoro-2-(triazol-2-yl)phenyl]-[(1r,6s)-4-[4-(trifluoromethyl)pyridin-2-yl]-4,7-diazabicyclo[4.2.0]octan-7-yl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C=2C=CC=C(C=2N2N=CC=N2)F)CN1C1=CC(C(F)(F)F)=CC=N1 LLRGSYGXXWURGI-CXAGYDPISA-N 0.000 claims 1
- DAYJKGFFLDEOFR-CZUORRHYSA-N [3-fluoro-2-(triazol-2-yl)phenyl]-[(1r,6s)-4-[6-(trifluoromethyl)pyridin-2-yl]-4,7-diazabicyclo[4.2.0]octan-7-yl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C=2C=CC=C(C=2N2N=CC=N2)F)CN1C1=CC=CC(C(F)(F)F)=N1 DAYJKGFFLDEOFR-CZUORRHYSA-N 0.000 claims 1
- XOSYGJTXILGMNE-IUODEOHRSA-N [3-fluoro-2-(triazol-2-yl)phenyl]-[(1r,6s)-4-[6-(trifluoromethyl)pyrimidin-4-yl]-4,7-diazabicyclo[4.2.0]octan-7-yl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C=2C=CC=C(C=2N2N=CC=N2)F)CN1C1=CC(C(F)(F)F)=NC=N1 XOSYGJTXILGMNE-IUODEOHRSA-N 0.000 claims 1
- JCWXAQBOQLLUDY-UHFFFAOYSA-N [4-(1,3-benzoxazol-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-(2,6-dimethoxyphenyl)methanone Chemical compound COC1=CC=CC(OC)=C1C(=O)N1C2CN(C=3OC4=CC=CC=C4N=3)CCC2C1 JCWXAQBOQLLUDY-UHFFFAOYSA-N 0.000 claims 1
- NFDWZLRKHQEVLP-UHFFFAOYSA-N [4-(1,3-benzoxazol-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]-(2-phenylphenyl)methanone Chemical compound C1C2CCN(C=3OC4=CC=CC=C4N=3)CC2N1C(=O)C1=CC=CC=C1C1=CC=CC=C1 NFDWZLRKHQEVLP-UHFFFAOYSA-N 0.000 claims 1
- RHAQHUQDCKSIOL-DYESRHJHSA-N [4-methoxy-2-(triazol-2-yl)phenyl]-[(1r,6s)-4-(4,5,6-trimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C2=CC=C(C=C2N2N=CC=N2)OC)CN1C1=NC(C)=C(C)C(C)=N1 RHAQHUQDCKSIOL-DYESRHJHSA-N 0.000 claims 1
- ZMSRLKXGHBGSKN-AUUYWEPGSA-N [4-methoxy-2-(triazol-2-yl)phenyl]-[(1r,6s)-4-[4-(trifluoromethyl)pyridin-2-yl]-4,7-diazabicyclo[4.2.0]octan-7-yl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C2=CC=C(C=C2N2N=CC=N2)OC)CN1C1=CC(C(F)(F)F)=CC=N1 ZMSRLKXGHBGSKN-AUUYWEPGSA-N 0.000 claims 1
- PVMSLIIKRSPXBQ-CXAGYDPISA-N [4-methoxy-2-(triazol-2-yl)phenyl]-[(1r,6s)-4-[4-(trifluoromethyl)pyrimidin-2-yl]-4,7-diazabicyclo[4.2.0]octan-7-yl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C2=CC=C(C=C2N2N=CC=N2)OC)CN1C1=NC=CC(C(F)(F)F)=N1 PVMSLIIKRSPXBQ-CXAGYDPISA-N 0.000 claims 1
- VEYPYYVAYRDHBG-UHFFFAOYSA-N [5-(2-fluorophenyl)-2-methyl-1,3-thiazol-4-yl]-(4-quinoxalin-6-yl-4,7-diazabicyclo[4.2.0]octan-7-yl)methanone Chemical compound S1C(C)=NC(C(=O)N2C3CN(CCC3C2)C=2C=C3N=CC=NC3=CC=2)=C1C1=CC=CC=C1F VEYPYYVAYRDHBG-UHFFFAOYSA-N 0.000 claims 1
- JWRRTEMALCSEPJ-OXQOHEQNSA-N [5-fluoro-2-(triazol-2-yl)phenyl]-[(1r,6s)-4-(4,5,6-trimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]methanone Chemical compound CC1=C(C)C(C)=NC(N2C[C@H]3N(C[C@H]3CC2)C(=O)C=2C(=CC=C(F)C=2)N2N=CC=N2)=N1 JWRRTEMALCSEPJ-OXQOHEQNSA-N 0.000 claims 1
- RHFDARLFDIHFTH-RDTXWAMCSA-N [5-fluoro-2-(triazol-2-yl)phenyl]-[(1r,6s)-4-(4-methylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]methanone Chemical compound CC1=CC=NC(N2C[C@H]3N(C[C@H]3CC2)C(=O)C=2C(=CC=C(F)C=2)N2N=CC=N2)=N1 RHFDARLFDIHFTH-RDTXWAMCSA-N 0.000 claims 1
- BJJXKASZDJGHDW-FZKQIMNGSA-N [5-fluoro-2-(triazol-2-yl)phenyl]-[(1r,6s)-4-[4-(trifluoromethyl)pyridin-2-yl]-4,7-diazabicyclo[4.2.0]octan-7-yl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C=2C(=CC=C(C=2)F)N2N=CC=N2)CN1C1=CC(C(F)(F)F)=CC=N1 BJJXKASZDJGHDW-FZKQIMNGSA-N 0.000 claims 1
- CWIQEEQAULWTRE-MLGOLLRUSA-N [5-fluoro-2-(triazol-2-yl)phenyl]-[(1r,6s)-4-[4-(trifluoromethyl)pyrimidin-2-yl]-4,7-diazabicyclo[4.2.0]octan-7-yl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C=2C(=CC=C(C=2)F)N2N=CC=N2)CN1C1=NC=CC(C(F)(F)F)=N1 CWIQEEQAULWTRE-MLGOLLRUSA-N 0.000 claims 1
- ZDZQWBZVNPMBHS-CXAGYDPISA-N [5-fluoro-2-(triazol-2-yl)phenyl]-[(1r,6s)-4-[6-(trifluoromethyl)pyridin-2-yl]-4,7-diazabicyclo[4.2.0]octan-7-yl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C=2C(=CC=C(C=2)F)N2N=CC=N2)CN1C1=CC=CC(C(F)(F)F)=N1 ZDZQWBZVNPMBHS-CXAGYDPISA-N 0.000 claims 1
- URQSGYXCJATHTI-MLGOLLRUSA-N [5-fluoro-2-(triazol-2-yl)phenyl]-[(1r,6s)-4-[6-(trifluoromethyl)pyrimidin-4-yl]-4,7-diazabicyclo[4.2.0]octan-7-yl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C=2C(=CC=C(C=2)F)N2N=CC=N2)CN1C1=CC(C(F)(F)F)=NC=N1 URQSGYXCJATHTI-MLGOLLRUSA-N 0.000 claims 1
- YRYYISJZOFBAKI-DYESRHJHSA-N [5-methoxy-2-(triazol-2-yl)phenyl]-[(1r,6s)-4-(4,5,6-trimethylpyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C=2C(=CC=C(C=2)OC)N2N=CC=N2)CN1C1=NC(C)=C(C)C(C)=N1 YRYYISJZOFBAKI-DYESRHJHSA-N 0.000 claims 1
- BTDMODRYHJWHFY-OPAMFIHVSA-N [5-methoxy-2-(triazol-2-yl)phenyl]-[(1r,6s)-4-(4-methyl-6,7-dihydro-5h-cyclopenta[d]pyrimidin-2-yl)-4,7-diazabicyclo[4.2.0]octan-7-yl]methanone Chemical compound N1([C@@H]2CN(CC[C@@H]2C1)C=1N=C(C)C=2CCCC=2N=1)C(=O)C1=CC(OC)=CC=C1N1N=CC=N1 BTDMODRYHJWHFY-OPAMFIHVSA-N 0.000 claims 1
- OGYTURZSQDMGIH-CXAGYDPISA-N [5-methoxy-2-(triazol-2-yl)phenyl]-[(1r,6s)-4-[4-(trifluoromethyl)pyrimidin-2-yl]-4,7-diazabicyclo[4.2.0]octan-7-yl]methanone Chemical compound C([C@@H]1CN([C@@H]1C1)C(=O)C=2C(=CC=C(C=2)OC)N2N=CC=N2)CN1C1=NC=CC(C(F)(F)F)=N1 OGYTURZSQDMGIH-CXAGYDPISA-N 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000008784 apnea Diseases 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims 1
- 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 150000005829 chemical entities Chemical class 0.000 claims 1
- 201000001883 cholelithiasis Diseases 0.000 claims 1
- 208000001130 gallstones Diseases 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 108060005714 orexin Proteins 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25451709P | 2009-10-23 | 2009-10-23 | |
| US61/254,517 | 2009-10-23 | ||
| PCT/US2010/053611 WO2011050202A1 (en) | 2009-10-23 | 2010-10-21 | Fused heterocyclic compounds as orexin receptor modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015230474A Division JP6170121B2 (ja) | 2009-10-23 | 2015-11-26 | オレキシン受容体調節因子としての縮合複素環式化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013508405A JP2013508405A (ja) | 2013-03-07 |
| JP2013508405A5 true JP2013508405A5 (enExample) | 2013-12-05 |
| JP5848251B2 JP5848251B2 (ja) | 2016-01-27 |
Family
ID=43221929
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012535386A Expired - Fee Related JP5848251B2 (ja) | 2009-10-23 | 2010-10-21 | オレキシン受容体調節因子としての縮合複素環式化合物 |
| JP2015230474A Expired - Fee Related JP6170121B2 (ja) | 2009-10-23 | 2015-11-26 | オレキシン受容体調節因子としての縮合複素環式化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015230474A Expired - Fee Related JP6170121B2 (ja) | 2009-10-23 | 2015-11-26 | オレキシン受容体調節因子としての縮合複素環式化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9062044B2 (enExample) |
| EP (1) | EP2491031B1 (enExample) |
| JP (2) | JP5848251B2 (enExample) |
| AR (1) | AR078732A1 (enExample) |
| CL (1) | CL2010001160A1 (enExample) |
| PE (1) | PE20110328A1 (enExample) |
| TW (1) | TW201141859A (enExample) |
| UY (1) | UY32967A (enExample) |
| WO (1) | WO2011050202A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2709668B2 (ja) | 1991-12-24 | 1998-02-04 | 宇部興産株式会社 | マンドレルの取外し装置 |
| WO2011029043A1 (en) * | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Heteroaryl btk inhibitors |
| ME03452B (me) | 2009-10-23 | 2020-01-20 | Janssen Pharmaceutica Nv | Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora |
| EP2491031B1 (en) * | 2009-10-23 | 2013-08-07 | Janssen Pharmaceutica N.V. | Fused heterocyclic compounds as orexin receptor modulators |
| WO2012085857A1 (en) | 2010-12-22 | 2012-06-28 | Actelion Pharmaceuticals Ltd | 3,8-diaza-bicyclo[4.2.0]oct-3-yl amides |
| WO2012145581A1 (en) | 2011-04-20 | 2012-10-26 | Janssen Pharmaceutica Nv | Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators |
| SI2776430T1 (sl) | 2011-11-08 | 2016-06-30 | Actelion Pharmaceuticals Ltd. | 2-(1,2,3-triazol-2-il)benzamidni in 3-(1,2,3-triazol-2-il)pikolinamidni derivati kot antagonisti oreksinskega receptorja |
| JP6346862B2 (ja) | 2012-02-07 | 2018-06-20 | エオラス セラピューティクス， インコーポレイテッド | オレキシンレセプターアンタゴニストとしての置換プロリン／ピペリジン |
| US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| DK2855453T3 (en) | 2012-06-04 | 2017-02-06 | Actelion Pharmaceuticals Ltd | Benzimidazol-proline derivatives |
| BR112015007516A2 (pt) | 2012-10-10 | 2017-07-04 | Actelion Pharmaceuticals Ltd | antagonistas do receptor de orexina que são derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)- pirrolidin-1-il]-metanona |
| CN103012293A (zh) * | 2012-12-13 | 2013-04-03 | 同济大学 | 一种抗失眠药物mk-4305中间体的合成方法 |
| CN105051040A (zh) | 2013-03-12 | 2015-11-11 | 埃科特莱茵药品有限公司 | 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物 |
| TW201444821A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代之哌啶化合物及其作為食慾素受體調節劑之用途 |
| TWI621618B (zh) | 2013-03-13 | 2018-04-21 | 比利時商健生藥品公司 | 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途 |
| TW201444849A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途 |
| TWI599567B (zh) | 2013-03-14 | 2017-09-21 | 健生藥品公司 | Ｐ２ｘ７調節劑 |
| WO2015073707A1 (en) | 2013-11-15 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating heart failure with agonists of hypocretin receptor 2 |
| SI3077391T1 (sl) | 2013-12-04 | 2018-11-30 | Idorsia Pharmaceuticals Ltd | Uporaba benzimidazol-prolinskih derivatov |
| TW201613902A (en) | 2014-08-13 | 2016-04-16 | Eolas Therapeutics Inc | Difluoropyrrolidines as orexin receptor modulators |
| JP6715239B2 (ja) | 2014-09-11 | 2020-07-01 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換２−アザ二環式化合物及びオレキシン受容体調節因子としてのその使用 |
| US10196383B2 (en) | 2015-07-17 | 2019-02-05 | Sunshine Lake Pharma Co., Ltd. | Substituted quinazoline compounds and preparation and uses thereof |
| US10370380B2 (en) | 2015-11-23 | 2019-08-06 | Sunshine Lake Pharma Co., Ltd. | Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof |
| US10894789B2 (en) | 2016-02-12 | 2021-01-19 | Astrazeneca Ab | Halo-substituted piperidines as orexin receptor modulators |
| KR20230116948A (ko) | 2016-03-10 | 2023-08-04 | 얀센 파마슈티카 엔.브이. | 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법 |
| MX392154B (es) | 2017-05-03 | 2025-03-21 | Idorsia Pharmaceuticals Ltd | Preparacion de derivados de acido 2-([1,2,3]triazol-2-il)-benzoico. |
| JP7413368B2 (ja) | 2018-09-28 | 2024-01-15 | ヤンセン ファーマシューティカ エヌ．ベー． | モノアシルグリセロールリパーゼ調節因子 |
| MA53721A (fr) | 2018-09-28 | 2021-09-15 | Janssen Pharmaceutica Nv | Modulateurs de la monoacylglycérol lipase |
| RS65638B1 (sr) * | 2018-11-14 | 2024-07-31 | Janssen Pharmaceutica Nv | Unapređene sintetičke metode pravljenja fuzionisanih heterocikličnih jedinjenja kao modulatora receptora oreksina |
| CN120097862A (zh) | 2019-08-07 | 2025-06-06 | 詹森药业有限公司 | 制备作为食欲素受体调节剂的(2h-1,2,3-三唑-2-基)苯基化合物的改进的合成方法 |
| CA3156100A1 (en) | 2019-09-30 | 2021-04-08 | Janssen Pharmaceutica Nv | Radiolabelled mgl pet ligands |
| CA3176946A1 (en) | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6375897B1 (en) | 2000-02-14 | 2002-04-23 | Ansys Technologies, Inc. | Urine collection cup |
| MY145722A (en) | 2000-04-27 | 2012-03-30 | Abbott Lab | Diazabicyclic central nervous system active agents |
| US6809105B2 (en) | 2000-04-27 | 2004-10-26 | Abbott Laboratories | Diazabicyclic central nervous system active agents |
| US7470710B2 (en) | 2001-06-28 | 2008-12-30 | Smithkline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| GB2383315B (en) | 2001-12-18 | 2005-04-06 | Christopher Donald Clarke | Vehicle imaging system |
| GB0130341D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| JP4498922B2 (ja) | 2002-07-09 | 2010-07-07 | アクテリオン ファーマシューティカルズ リミテッド | ７，８，９，１０−テトラヒドロ−６Ｈ−アゼピノ、６，７，８，９−テトラヒドロ−ピリドおよび２，３−ジヒドロ−２Ｈ−ピロロ［２，１−ｂ］−キナゾリノン誘導体 |
| NZ538749A (en) | 2002-10-11 | 2006-11-30 | Actelion Pharmaceuticals Ltd | Sulfonylamino-acetic acid derivatives and their use as orexin receptor antagonists |
| GB0225944D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| US20040242641A1 (en) | 2003-05-27 | 2004-12-02 | Buckley Michael J. | (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent |
| US20050065178A1 (en) | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
| US7399765B2 (en) | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
| EP1846409A1 (en) | 2004-11-24 | 2007-10-24 | Pfizer Limited | Octahydropyrrolo[3,4-c]pyrrole derivatives |
| DE102004061344A1 (de) | 2004-12-20 | 2006-07-06 | Siemens Ag | Verfahren zur sicheren Auslegung eines Systems, zugehörige Systemkomponente und Software |
| CN101193635A (zh) | 2005-05-13 | 2008-06-04 | 莱西肯医药有限公司 | 多环化合物及其使用方法 |
| WO2006124897A2 (en) | 2005-05-13 | 2006-11-23 | Lexicon Genetics Incorporated | Methods and compositions for improving cognition |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| JP2009506061A (ja) * | 2005-08-26 | 2009-02-12 | メルク エンド カムパニー インコーポレーテッド | ジアザスピロデカンオレキシン受容体拮抗薬 |
| JP2009531447A (ja) | 2006-03-29 | 2009-09-03 | メルク エンド カムパニー インコーポレーテッド | ジアゼパンオレキシン受容体アンタゴニスト |
| US20090105318A1 (en) | 2006-03-29 | 2009-04-23 | Coleman Paul J | Amidoethylthioether Orexin Receptor Antagonists |
| EP2049526A2 (en) | 2006-07-14 | 2009-04-22 | Merck & Co., Inc. | 2-substituted proline bis-amide orexin receptor antagonists |
| SI2049529T1 (sl) | 2006-07-14 | 2010-11-30 | Merck Sharp & Dohme | Substituiran diazepan oreksin receptor antagonist |
| EP2049110B1 (en) * | 2006-07-14 | 2014-08-20 | Merck Sharp & Dohme Corp. | Bridged diazepan orexin receptor antagonists |
| ES2345130T3 (es) | 2006-09-18 | 2010-09-15 | F. Hoffmann-La Roche Ag | Derivados de octahidropirrolo(3,4-c)pirrol y su uso como antiviricos. |
| US20080153811A1 (en) | 2006-11-07 | 2008-06-26 | Joseph Barbosa | Methods of Treating Cognitive Impairment and Dementia |
| PE20081229A1 (es) * | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| WO2008143856A1 (en) | 2007-05-18 | 2008-11-27 | Merck & Co., Inc. | Oxo bridged diazepan orexin receptor antagonists |
| FR2918061B1 (fr) | 2007-06-28 | 2010-10-22 | Sanofi Aventis | Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique. |
| FR2918986B1 (fr) | 2007-07-19 | 2009-09-04 | Sanofi Aventis Sa | Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique |
| ES2400830T3 (es) | 2007-08-15 | 2013-04-12 | Actelion Pharmaceuticals Ltd. | Derivados de 1,2-diamido-etileno como antagonistas de orexina |
| EP2214676B1 (en) | 2007-10-29 | 2012-11-21 | Merck Sharp & Dohme Corp. | Substituted diazepan orexin receptor antagonists |
| EP2058001A1 (en) | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Enhancement of immunogenicity of antigens |
| KR101204213B1 (ko) | 2007-12-21 | 2012-11-26 | 에프. 호프만-라 로슈 아게 | 오렉신 수용체 길항제로서의 헤테로아릴 유도체 |
| CN101952286A (zh) | 2007-12-21 | 2011-01-19 | 阿斯利康(瑞典)有限公司 | 用于治疗和雄激素受体有关的病症的双环衍生物 |
| GB0806536D0 (en) | 2008-04-10 | 2008-05-14 | Glaxo Group Ltd | Novel compounds |
| AR072899A1 (es) | 2008-08-07 | 2010-09-29 | Merck Sharp & Dohme | Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad. |
| US8129384B2 (en) | 2008-10-09 | 2012-03-06 | Glaxo Group Limited | Imidazo[1,2-a]pyrazines as orexin receptor antagonists |
| US8093255B2 (en) | 2008-10-09 | 2012-01-10 | Glaxo Group Limited | Imidazo[1,2-A]pyrimidines as orexin receptor antagonists |
| AU2009307921A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | Disubstituted azepan orexin receptor antagonists |
| WO2010048013A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted morpholine orexin receptor antagonists |
| JP2012506374A (ja) | 2008-10-21 | 2012-03-15 | メルク・シャープ・エンド・ドーム・コーポレイション | ２，５−二置換ピペリジンオレキシン受容体アンタゴニスト |
| AU2009307915A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted piperidine orexin receptor antagonists |
| AU2009307918A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,4-disubstituted pyrrolidine orexin receptor antagonists |
| EP2349262B1 (en) | 2008-10-30 | 2014-06-25 | Merck Sharp & Dohme Corp. | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists |
| MX2011004551A (es) | 2008-10-30 | 2011-05-25 | Merck Sharp & Dohme | Antagonistas del receptor de orexina de isonicotinamida. |
| EP2349267B1 (en) | 2008-10-30 | 2014-06-25 | Merck Sharp & Dohme Corp. | Pyridazine carboxamide orexin receptor antagonists |
| JP2012509912A (ja) | 2008-11-26 | 2012-04-26 | グラクソ グループ リミテッド | 新規の化合物 |
| EP2358712A1 (en) | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
| WO2010060470A1 (en) | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
| CA2745433A1 (en) | 2008-12-02 | 2010-06-10 | Glaxo Group Ltd. | N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof |
| KR20110091581A (ko) | 2008-12-02 | 2011-08-11 | 글락소 그룹 리미티드 | Ｎ-｛［1ｒ,4ｓ,6ｒ-3-(2-피리디닐카르보닐)-3-아자비시클로［4.1.0］헵트-4-일］메틸｝-2-헤테로아릴아민 유도체 및 그의 용도 |
| GB0823467D0 (en) | 2008-12-23 | 2009-01-28 | Glaxo Group Ltd | Novel Compounds |
| EP2491031B1 (en) * | 2009-10-23 | 2013-08-07 | Janssen Pharmaceutica N.V. | Fused heterocyclic compounds as orexin receptor modulators |
-
2010
- 2010-10-21 EP EP10773478.2A patent/EP2491031B1/en active Active
- 2010-10-21 WO PCT/US2010/053611 patent/WO2011050202A1/en not_active Ceased
- 2010-10-21 JP JP2012535386A patent/JP5848251B2/ja not_active Expired - Fee Related
- 2010-10-21 US US13/503,298 patent/US9062044B2/en active Active
- 2010-10-22 CL CL2010001160A patent/CL2010001160A1/es unknown
- 2010-10-22 PE PE2010000998A patent/PE20110328A1/es not_active Application Discontinuation
- 2010-10-22 AR ARP100103875A patent/AR078732A1/es unknown
- 2010-10-22 TW TW099136021A patent/TW201141859A/zh unknown
- 2010-10-25 UY UY0001032967A patent/UY32967A/es not_active Application Discontinuation
-
2015
- 2015-11-26 JP JP2015230474A patent/JP6170121B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12378254B2 (en) | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | |
| JP2013508404A5 (enExample) | ||
| JP2022531801A5 (enExample) | ||
| JP2013508403A5 (enExample) | ||
| AU2012299080B2 (en) | Pyrimidine PDE10 inhibitors | |
| US20140171430A1 (en) | Disubstituted octahydropyrrolo [3,4-c] pyrroles as orexin receptor modulators | |
| US9266881B2 (en) | Triazolopyridinone PDE10 inhibitors | |
| JP2019514878A5 (enExample) | ||
| JP2016500671A5 (enExample) | ||
| US20120202783A1 (en) | Fused heterocyclic compounds as orexin receptor modulators | |
| RU2015132181A (ru) | Фтор-[1,3]-оксазины в качестве ингибиторов васе1 | |
| US20140256708A1 (en) | 1,3 substituted azetidine pde10 inhibitors | |
| JP2018537408A5 (enExample) | ||
| US8785467B2 (en) | Alkoxy pyrimidine PDE10 inhibitors | |
| JP2016507551A5 (enExample) | ||
| US20140249134A1 (en) | Triazolyl pde10 inhibitors | |
| JP2016522231A5 (enExample) | ||
| US8975261B2 (en) | Aryloxmethyl cyclopropane derivatives as PDE10 inhibitors | |
| RU2014150494A (ru) | Пирролидиногетероциклы | |
| US9663513B2 (en) | Pyrimidine PDE10 inhibitors | |
| TWI925413B (zh) | Rho相關蛋白激酶抑制劑 | |
| RU2021107655A (ru) | Соединения триазоло-пиримидина и их применение |